Phase II Study of Oxaliplatin and Taxotere in Metastatic Bladder Cancer
To test the combination of oxaliplatin chemotherapy in combination with taxotere
chemotherapy in patients with advanced bladder cancer who have failed one prior
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Tolerability of the this combination in patients with recurrent metastatic bladder cancer.
Dr. Sandy Srinivas
United States: Food and Drug Administration
|Stanford University School of Medicine||Stanford, California 94305-5317|